



Effectiveness and safety of bedaquiline-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis: a multicentre study.

Journal:	<i>European Respiratory Journal</i>
Manuscript ID	ERJ-00387-2017
Manuscript Type:	Original Article
Date Submitted by the Author:	23-Feb-2017
Complete List of Authors:	<p>Borisov, Sergey Dheda, Keertan; University of Cape Town, Department of Medicine Enwerem, Martin Romero Leyet, Rodolfo D'Ambrosio, Lia; Maugeri Care and Research Institute, WHO Collaborating Centre for TB & Lung Diseases Centis, Rosella; S. Maugeri Foundation, WHO Collaborating Centre for TB; SOTGIU, Giovanni; University of Sassari Medical School, Department of Biomedical Sciences, University of Sassari ; Tiberi, Simon Alffenaar, Jan-Willem; University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology Maryandyshev, Andrey Belilovski, Evgeny Ganatra, Shashank; P.D. Hinduja Hospital And Medical Research Centre, Department of Pulmonary Medicine Skrahina, Alena; The Republican Research and Practical Centre for Pulmonology and TB, Clinical Akkerman, Onno; University Medical Center Groningen, Department of Pulmonology and Tuberculosis Aleksa, Alena ; Grodnenskij gosudarstvennyj medicinskij universitet, Phisiopulmonology Amale, Rohit Artsukevich, Janina Bruchfeld, Judith; Karolinska Institute Solna and Karolinska University Hospital, Unit of Infectious Diseases, Department of Medicine Caminero, Jose Antonio; Hospital Geenal de Gran Canaria , Neumología Carpena Martinez, Isabel Codecasa, Luigi; Niguarda Ca'Granda Hospital, Villa Marelli Institute Dalcolmo, Margareth ; Fundacao Oswaldo Cruz, Helio Fraga Institute Denholm, Justin; The Peter Doherty Institute, The Victorian Tuberculosis Program Douglas, Paul Duarte, Raquel; CDP de Vila Nova de Gaia, ; Faculdade de Medicina do Porto, Esmail, Aliasgar</p>

1	
2	
3	
4	Fadul, Mohammed
5	Filippov, Alexey
6	Davies-Forsman, Lina; Karolinska Institutet, Department of Medicine, Unit
7	of Infectious Disease; Karolinska Universitetssjukhuset, Infectious Disease
8	Gaga, Mina; Athens Chest Hospital, 7th Respiratory Medicine Dept
9	García-Fuertes, Julia-Amaranta
10	García-García, José-María; Hospital San Agustin, Pneumology
11	Gualano, Gina; INMI, Respiratory Infectious Diseases Unit
12	Jonsson, Jerker
13	Kunst, Heinke
14	Lau, Jillian
15	Mastrapa, Barbara; Gordon Hospital,
16	Teran Troya, Jorge Lazaro
17	Manga, Selene
18	Manika, Katerina; Aristotle University of Thessaloniki, Pulmonary
19	Department;
20	González Montaner, Pablo
21	Mullerpattan, Jai; P.D. Hinduja National Hospital and MRC, Respiratory
22	Medicine
23	Oelofse, Suzette
24	Ortelli, Martina
25	Palmero, Domingo ; Hospital Dr. F. J. Muñiz, Pulmonology
26	Palmieri, Fabrizio; L Spallanzani National Institute for infectious disease,
27	Clinical
28	Papalia, Antonella
29	Papavasileiou, Apostolos
30	Payen, Marie-Christine; Saint Pierre University Hospital, Infectious Disease
31	Pontali, Emanuele; Galliera Hospital,
32	Robalo Cordeiro, Carlos; University Hospital of Coimbra, Department of
33	Pulmonology and Allergy
34	Saderi, Laura
35	Sadutshang, Tsetan Dorji ; Delek Hospital, TB Department
36	Sanukevich, Tatsiana
37	Solodovnikova, Varvara
38	Spanevello, Antonio; Istituti Clinici Scientifici Maugeri SpA SB,
39	Dipartimento di Medicina e Riabilitazione Cardio Respiratoria; Universita
40	degli Studi dell'Insubria, Dipartimento di Medicina Clinica e Sperimentale
41	Topgyal, Sonam
42	Toscanini, Federica
43	Tramontana, Adrian
44	Udwadia, Zarir; P.D. Hinduja Hospital And Medical Research Centre,
45	Uebel, Kerry
46	Viggiani, Pietro
47	White, Veronica
48	Zumla, Alimuddin; University of Zambia-University College London Medical
49	School Research and Training Projec, University Teaching Hospital;
50	University College London, and NIHR Biomedical Research Centre,
51	University College London Hospitals, Division of Infection and Immunity
52	Migliori, Giovanni Battista; S. Maugeri Foundation, Who Collaborating
53	Centre for TB;
54	
55	
56	
57	
58	
59	
60	

Key Words: MDR-TB, XDR-TB, bedaquiline, safety, Tolerability, effectiveness

Effectiveness and safety of bedaquiline-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis: a multicentre study.

Sergey E. Borisov¹, Keertan Dheda², Martin Enwerem³, Rodolfo Romero Leyet⁴, Lia D'Ambrosio^{5,6}, Rosella Centis⁵, Giovanni Sotgiu⁷, Simon Tiberi^{8,9}, Jan-Willem Alffenaar¹⁰, Andrey Maryandyshev¹¹, Evgeny Belilovski¹, Shashank Ganatra¹², Alena Skrahina¹³, Onno Akkerman^{14,15}, Alena Aleksa¹⁶, Rohit Amale¹², Janina Artsukevich¹⁶, Judith Bruchfeld¹⁷, Jose A. Caminero^{18,19}, Isabel Carpena Martinez²⁰, Luigi Codecasa²¹, Margareth Dalcolmo²², Justin Denholm²³, Paul Douglas²⁴, Raquel Duarte²⁵, Aliasgar Esmail²⁶, Mohammed Fadul²⁶, Alexey Filippov¹, Lina Davies Forsman¹⁷, Mina Gaga²⁷, Julia-Amaranta Garcia-Fuertes²⁸, José-María García-García²⁹, Gina Gualano³⁰, Jerker Jonsson³¹, Heinke Kunst⁹, Jillian S. Lau³², Barbara Lazaro Mastrapa³³, Jorge Lazaro Teran Troya³³, Selene Manga³⁴, Katerina Manika³⁵, Pablo González Montaner³⁶, Jai Mullerpattan¹², Suzette Oelofse²⁶, Martina Orтели³⁷, Domingo Juan Palmero³⁶, Fabrizio Palmieri³⁰, Antonella Papalia³⁸, Apostolos Papavasileiou³⁹, Marie-Christine Payen⁴⁰, Emanuele Pontali⁴¹, Carlos Robalo Cordeiro⁴², Laura Saderi⁷, Tsetan Dorji Sadutshang⁴³, Tatsiana Sanukevich¹⁶, Varvara Solodovnikova¹³, Antonio Spanevello^{44,45}, Sonam Topgyal⁴³, Federica Toscanini⁴⁶, Adrian R. Tramontana⁴⁷, Zarir Farokh Udwadia¹², Kerry Uebel⁴⁸, Pietro Viggiani³⁸, Veronica White⁴⁹, Alimuddin Zumla⁵⁰ and Giovanni Battista Migliori⁵

1. Moscow Research and Clinical Center for TB Control, Moscow Government's Health Department, Moscow, Russian Federation
2. UCT Lung Institute, Division of Pulmonology, University of Cape Town, Cape Town, South Africa
3. Amity Health Consortium, Country Club Estate, Johannesburg, South Africa
4. Clinical Unit, District Clinical Specialist Team, Namakwa District, Springbok, South Africa
5. World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Maugeri Care and Research Institute, Tradate, Italy
6. Public Health Consulting Group, Lugano, Switzerland
7. Clinical Epidemiology and Medical Statistics Unit, Department of Biomedical Sciences, University of Sassari, Sassari, Italy
8. Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom

- 1
- 2
- 3 9. Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary
- 4 University of London, London, United Kingdom, E1 2AT
- 5
- 6 10. University of Groningen, University Medical Center Groningen, Department of Clinical
- 7 Pharmacy and Pharmacology, Groningen, The Netherlands
- 8
- 9 11. Northern State Medical University, Arkhangelsk, Russian Federation
- 10
- 11 12. Department of Respiratory Medicine, P.D. Hinduja National Hospital and MRC, Mumbai,
- 12 India
- 13
- 14 13. Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus
- 15
- 16 14. University of Groningen, University Medical Center Groningen, Tuberculosis Center
- 17 Beatrixoord, Haren, The Netherlands
- 18
- 19 15. University of Groningen, University Medical Center Groningen, Department of Pulmonary
- 20 Diseases & Tuberculosis, Groningen, The Netherlands
- 21
- 22 16. Department of Phthisiology, Grodno State Medical University, GRCC “Phthisiology”, Grodno,
- 23 Belarus
- 24
- 25 17. Unit of Infectious Diseases, Department of Medicine, Solna, Karolinska Institute; Department
- 26 of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
- 27
- 28 18. Pneumology Department, Hospital General de Gran Canaria “Dr. Negrin”, Las Palmas de Gran
- 29 Canaria, Spain
- 30
- 31 19. MDR-TB Unit. Tuberculosis Division. International Union against Tuberculosis and Lung
- 32 Disease (The Union), Paris, France
- 33
- 34 20. General University Hospital Morales Meseguer, Murcia, Spain
- 35
- 36 21. TB Reference Centre, Villa Marelli Institute, Milan, Italy
- 37
- 38 22. Hélio Fraga Reference Center, Fiocruz / MoH, Rio de Janeiro, Brazil
- 39
- 40 23. Victorian Tuberculosis Program, Melbourne Health; Department of Microbiology and
- 41 Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity,
- 42 Melbourne, Australia
- 43
- 44 24. Health Policy and Performance Branch, Health Services and Policy Division, Department of
- 45 Immigration and Border Protection, Sydney, Australia
- 46
- 47 25. National Reference Centre for MDR-TB, Hospital Centre Vila Nova de Gaia, Department of
- 48 Pneumology; Public Health Science and Medical Education Department, Faculty of Medicine,
- 49 University of Porto, Porto, Portugal
- 50
- 51 26. UCT Lung Institute, Lung Infection and Immunity Unit. Division of Pulmonology, Department
- 52 of Medicine, University of Cape Town, & Groote Schuur Hospital, Cape Town, South Africa
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3 27. 7th Respiratory Medicine Department, Athens Chest Hospital, Athens, Greece
- 4
- 5 28. Bronchiectasis Unit - Respiratory Department, Hospital Universitario Araba, Vitoria-Gasteiz,
- 6 Spain
- 7
- 8 29. Tuberculosis Research Programme, SEPAR, Barcelona, Spain
- 9
- 10 30. Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases 'L.
- 11 Spallanzani', IRCCS, Rome, Italy
- 12
- 13 31. National TB Surveillance Unit, Public Health Agency, Stockholm, Sweden
- 14
- 15 32. Department of Infectious Diseases, Box Hill Hospital, Box Hill, Victoria, Australia
- 16
- 17 33. Harry Surtie Hospital, Upington, South Africa
- 18
- 19 34. Department of Infectious Diseases, University National San Antonio Abad Cusco, Cusco, Perú
- 20
- 21 35. Pulmonary Department, "G. Papanikolaou" Hospital, Aristotle University, Thessaloniki,
- 22 Greece
- 23
- 24 36. Pulmonology Division, Municipal Hospital F. J. Muñoz, Buenos Aires, Argentina
- 25
- 26 37. Pneumology Department, University of Insubria, Varese, Italy
- 27
- 28 38. AOVV Eugenio Morelli Hospital, Reference Hospital for MDR and HIV-TB, Sondalo, Italy
- 29
- 30 39. MDR-TB Unit, Athens Chest Hospital, Ministry of Health, Athens, Greece
- 31
- 32 40. Division of Infectious Diseases, CHU Saint-Pierre, Université Libre de Bruxelles (ULB),
- 33 Brussels, Belgium
- 34
- 35 41. Department of Infectious Diseases, Galliera Hospital, Genoa, Italy
- 36
- 37 42. Coimbra Medical School, Pneumology Department, Coimbra University Hospital, Coimbra,
- 38 Portugal; European Respiratory Society
- 39
- 40 43. Delek Hospital, Dharamshala, India
- 41
- 42 44. Pneumology Department, Maugeri Care and Research Institute, Tradate, Italy
- 43
- 44 45. Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
- 45
- 46 46. University Hospital San Martino, Care and Research Institute, National Institute for Cancer
- 47 Research, Genoa, Italy
- 48
- 49 47. Department of Infectious Diseases, Western Hospital, Footscray, Victoria, Australia
- 50
- 51 48. Centre for Health Systems Research and Development, University of the Free State,
- 52 Bloemfontein, South Africa
- 53
- 54 49. Department of Respiratory Medicine, Barts Healthcare NHS Trust, London, United Kingdom
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3 50. Division of Infection and Immunity, University College London and NIHR Biomedical
4 Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom
5
6
7
8
9
10
11
12

13 **Address for Correspondence:** G.B. Migliori, World Health Organization Collaborating Centre for
14 Tuberculosis and Lung Diseases, Maugeri, Care and Research Institute, Via Roncaccio 16, 21049,
15 Tradate, Italy. E-mail: giovannibattista.migliori@icsmaugeri.it
16
17
18
19
20
21

22 **Running Head** Bedaquiline to treat M/XDR-TB
23

24 **Keywords** MDR-TB, XDR-TB, bedaquiline, effectiveness, safety, tolerability.
25

26 **Short sentence:** Bedaquiline is safe and effective in treating MDR and XDR-TB patients.
27
28

29 **Word count** 2,803 words
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Summary (200/200 words)

Large studies on bedaquiline used programmatically to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) are lacking. The study aim is to evaluate effectiveness and safety of bedaquiline-containing regimens in a large retrospective, observational study conducted in 25 centres and 15 countries in all continents.

428 MDR-TB cases were analysed (61.5% males; 22.1% HIV-positive, 45.6% XDR-TB). MDR-TB cases were admitted to hospital for 179 days (92-280) and exposed to bedaquiline for 168 days (86-180). Treatment regimens included linezolid, moxifloxacin and carbapenems (82.0%, 58.4%, and 15.3% of cases, respectively).

Sputum smear and culture conversion rates in MDR-TB cases were 63.6 and 30.1% at 30 days, 81.1 and 56.7% at 60 days; 85.5 and 80.5% at 90 days and 90.9 and 91.8%, respectively at the end of treatment. The time to smear and culture conversion was 34 (30-60) and 60 (33-90) days.

Out of 247 culture-confirmed MDR-TB cases completing treatment, 71.3% achieved success (62.4% cured; 8.9% completed treatment), 13.4% died, 7.3% defaulted, 7.7% failed.

Twenty-seven rifampicin-resistant cases were also described.

Bedaquiline was interrupted due to adverse events in 5.8% of cases. A single case died having electrocardiographic abnormalities probably non-bedaquiline related.

Bedaquiline-containing regimens achieved high conversion and success rates under programmatic conditions.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

A total of 480,000 cases of multidrug-resistant tuberculosis (MDR-TB) and 100,000 of rifampicin-resistant (RR)-TB eligible for MDR-TB treatment were estimated by the World Health Organization (WHO) to have occurred in 2015, with 190,000 deaths [1]. Over half of the estimated MDR-TB cases occurred in India, China, Russian Federation, and the other Former Soviet Union countries, as well as in South Africa [1]. Globally, about 10% of the MDR-TB strains meet the criteria defining XDR-TB (resistance to any fluoroquinolone and at least one second-line injectable drug) [1,2].

Treatment for M/XDR-TB is long, expensive, and characterised by a high rate of adverse events [3-19]. The main difficulty is the identification of at least four active drugs to design an effective regimen [3,4,7,8, 12-15].

The previous stepwise approach based on the hierarchical use of first- and second-line anti-TB drugs classified into five groups has been recently modified by WHO. The new classification includes 4 groups of drugs (A: fluoroquinolones; B: second-line injectable agents; C: other core second-line agents and D: add-on agents, subdivided into the sub-groups D1, D2 and D3) [7,12].

Two newly available drugs, delamanid, [16-18] and bedaquiline [19-25], together with some repurposed drugs (linezolid [13,26-32], carbapenems [33-38] and clofazimine [39] among others [40-43]) are presently pivotal in ongoing scientific discussions.

The information available today on bedaquiline is still limited to phase 2 studies in relatively small cohorts treated under clinical trials conditions, the largest study not exceeding 233 patients [19-24]. In particular, at this present time, no study of size informs us on the effectiveness, safety, and tolerability of bedaquiline, in different continents and programmatic conditions.

Given the concerns around the adverse events of bedaquiline (particularly QT-prolongation, potentially at highest risk when added to fluoroquinolones – moxifloxacin, levofloxacin, ofloxacin-, clofazimine, delamanid and methadone amongst others), additional evidence on its safety, apart from that provided by the registration trials, is urgently needed [44-46].

Recently, TB reference centres belonging to the International Bedaquiline Study Group (IBSG, a network merging the centres belonging to the International Carbapenems Study Group-ICSG [36-38] and the ERS/ALAT and Brazilian Society collaborative projects [47,48] coordinated by the

ERS TB Collaborating Centre) conducted an observational study on the therapeutic contribution of bedaquiline added to a background regimen (as per WHO guidelines) when treating MDR- and XDR-TB cases.

The aim of the present study is to evaluate the effectiveness, safety, and tolerability of bedaquiline within optimised background regimens in a large multi-centre cohort of MDR- and XDR-TB patients treated under programmatic conditions.

Material and Methods

The methodological approach adopted for this study is similar to that described in previous ICSG studies [36-38]. Twenty-five MDR-TB reference centres located in 15 countries in Africa, Asia, Europe, Oceania and Southern America (Argentina, Australia, Belarus, Belgium, Greece, India, Italy, Netherlands, Peru, Portugal, Russian Federation, South Africa, Spain, Sweden, and United Kingdom) retrospectively recruited RR- and culture-confirmed MDR-TB patients aged ≥ 15 years. An MDR-TB case was defined as an individual with TB disease caused by *M. tuberculosis* strains phenotypically resistant to at least isoniazid and rifampicin. RR-TB cases were those diagnosed through Xpert MTB/RIF® (Cepheid, Sunnyvale USA) complemented by line probe assays. XDR-TB cases were those whose disease was due to MDR *M. tuberculosis* strains with additional resistance to any fluoroquinolone and one of the second-line injectable drugs (i.e., amikacin, capreomycin, and kanamycin) [1,8].

Patients starting their treatment between January 1st 2008 and August 30th 2016 were consecutively enrolled based on their exposure to bedaquiline during the intensive and the continuation phase. Bedaquiline was made accessible either under compassionate use, within the expanded access programmes or purchased by respective countries.

An individualised TB regimen was administered following the results of the drug susceptibility test (DST) carried out by externally quality-assured laboratories [36-38]. RR cases were managed according to the national guidelines in force in their respective countries (South Africa) [49]. Physicians were free to prescribe the accompanying anti-TB treatment to obtain the best possible regimen in their setting and, consequently, no specific protocol or method beyond local guidelines was followed.

Bedaquiline was administered at the recommended dosage of 400 mg once a day for 14 days then 200 mg three times a week for 22 weeks.

A standardized ad-hoc e-form was used to collect epidemiological (i.e., age, place of birth and residence, gender, migrant status from a TB high-incidence country), clinical (i.e., cardiac and

1
2
3 thyroid disorders, HIV-testing, HIV-infection status, administration of HIV drugs, previous TB
4 diagnosis and treatment, previous treatment outcomes, radiological findings, TB therapy and related
5 adverse events, duration of exposure to bedaquiline, delamanid, linezolid, carbapenems, adjuvant
6 surgery, sputum smear and culture positivity at the baseline, and during treatment-at 30, 60, and 90
7 days-, time to sputum smear and culture conversion, WHO treatment outcomes, duration of hospital
8 stay), and microbiological (i.e., DST results) data from medical records.

9
10
11 The ethical approval for the retrospective collection of clinical data was obtained by the
12 coordinating centre.

13
14
15 Culture-confirmed MDR- and RR-TB cases were analysed separately. MDR- and XDR-TB cases'
16 outcomes were compared by setting.

17
18
19 Qualitative and quantitative variables were summarised with percentages and medians (interquartile
20 ranges –IQR). Chi-square or Fisher exact and Mann-Whitney tests were used to statistically
21 compare qualitative and quantitative variables, respectively.

22
23
24 A p-value of less than 0.05 was considered statistically significant. Statistical computations were
25 performed with Stata 13.0 (StataCorp, College Station, TX).

26 27 28 29 30 Results

31
32
33
34 Demographic, epidemiological and clinical characteristics of the patients are summarised in Table
35 1, treatment outcome results in Table 2-3 and safety and tolerability information on bedaquiline in
36 Table 4.

37
38
39 A total of 455 MDR- and RR-TB patients were recruited: 428 (94.1%) and 27 (5.9%) were
40 diagnosed by conventional culture and DST and by Xpert and line-probe assays, respectively.

41
42
43 Male (271, 59.6%) was the most prevalent gender in the cohort (263, 61.5%, VS. 8, 29.6%, in the
44 MDR- and RR-TB groups, respectively; $p=0.001$), and the median (IQR) age was 35 (27-44) years
45 (35, 27-44, VS. 31, 24-40, for MDR- and RR-TB groups, respectively; $p=0.16$).

46
47
48 The characteristics of the 428 culture-confirmed MDR-TB patients are summarised in Table 1.
49 Migrants from high to low TB incidence countries were 45 (10.5%).

50
51
52 The proportion of HIV co-infected patients was 22.1%; their median (IQR) CD4 cell count was
53 269/mm³ (168-470) and the majority (92, 97.9%) received antiretroviral therapy.

1
2
3 Pulmonary TB was diagnosed in 426 out of 428 (99.5%) cases, the extra-pulmonary locations being
4 abdominal and the nervous system (2). The percentages of sputum smear and culture positive cases
5 were 72.1% and 98.4%, respectively.
6
7

8
9 Less than half were affected by XDR-TB (195/428, 45.6%), with a median (IQR) number of drug
10 resistances of 3 (1-5). Overall, 334/428 (78.0%) cases were previously treated for TB.
11

12
13 The prevalence of drug resistance was as follows: streptomycin 185 (94.4%), pyrazinamide 145
14 (70.4%), fluoroquinolones 267 (64.5%), amikacin 131 (44.4%), capreomycin 127 (41.6%),
15 kanamycin 179 (59.3%), ethionamide 135 (59.7%), PAS 70 (35.7%), linezolid 4 (10.5%),
16 ethambutol 186 (77.5%), and cycloserine 20 (12.3%).
17
18
19

20
21 Treatment regimens included linezolid (82.0%), clofazimine (52.6%), moxifloxacin (58.4%),
22 second-line injectables (45.8%) and carbapenems (15.3%).
23

24
25 Patients were exposed to bedaquiline for a median (IQR) of 168 (86-180) days (Table 4). Five
26 (1.2%) patients underwent treatment with both delamanid and bedaquiline. Adjuvant surgical
27 therapy was performed in 55 (13%) cases.
28
29

30
31 The median (IQR range) treatment duration in the cohort was 18 (10-22) months.
32

33
34 Sputum smear and culture conversion rates were 63.6% and 30.1% at 30 days; 81.1% and 56.7% at
35 60 days; 85.5% and 80.5% at 90 days, and 90.0% and 91.8%, at the end of treatment (for those
36 completing it) respectively. The median (IQR) time to sputum smear and culture conversion was 34
37 (30-60) and 60 (33-90) days (Figure 1).
38
39

40
41 Out of 247 culture-confirmed MDR-TB cases completing treatment, 71.3% achieved success
42 (62.4% cured and 8.9% completed treatment), 13.4% died, 7.3% defaulted, and 7.7% failed.
43

44
45 Sputum smear and culture conversion rates at the end of treatment were not significantly different
46 among XDR- and MDR-TB cases ($p=0.73$ and 0.96 , respectively).
47

48
49 The treatment success rates were higher in Eastern Europe and in settings other than in Africa
50 (Table 3), including both MDR- and XDR-TB patients. The HIV co-infection prevalence in Africa,
51 Eastern Europe and remaining settings together was 88/190 (46.3%), 0/150 (0%) and 6/85 (7.1%),
52 respectively.
53
54

55
56 Figure 2 summarises the median values of the QTcF interval (QT interval in the electrocardiogram
57 corrected according to Fredericia formula) and its temporal trends in the cohort.
58
59
60

1
2
3 Adverse events potentially attributed to bedaquiline were reported in 80 of 413 (19.4%) cases where
4 this information was provided (Table 4). The majority of the adverse events described were
5 represented by nausea, peripheral neuropathy, and otovestibular toxicity.

6
7
8 In particular, 51 of 428 (11.9%) patients discontinued bedaquiline (25 or 5.8% -reporting adverse
9 events), of these 26 (51%) did so permanently.

10
11 Although we do not have the exact information on how many cases interrupted bedaquiline due to
12 QTcF increase, 24 of 247 (9.7%) experienced QTcF prolongation >500msec.

13
14 One patient was started on bedaquiline with a baseline QTcF of 553 msec, which then decreased to
15 536 at week 4 and 554 at week 8. A second patient, with a baseline QTcF of 352 msec, had a
16 transient increase (510 at week 3) and then a decline (358 at week 4): the clinician reported the
17 cause of death was not heart-related.

18
19 The median (IQR) exposure to bedaquiline amongst the 26 patients who permanently interrupted
20 was 69 (27.5-135) days, and 85.5 (44.3-160) days in those 33 patients who died.

21
22 Out of 33 who died, we have QT information on 21 (63.6%), no patient had a baseline QT >500
23 msec.

24
25
26 We have information of a single patient who died having ECG disturbances. The patient after 131
27 days of bedaquiline exposure had PVC (premature ventricular contraction) bigeminy and fatal
28 cardiac arrest. Interestingly, the QT was below the 'alert' threshold: 414 msec at baseline (QTcF:
29 438), with a maximum value of 462 at week 6 (QTcF: 462) then decreasing to 356 (QTcF: 398) at
30 week 16.

31
32
33 Furthermore, 104 out of 348 (29.9%) cases treated with linezolid reported adverse events attributed
34 to this drug; 16/58 (27.6%) of them (for whom final treatment data was available) permanently
35 discontinued linezolid.

36 37 38 Discussion

39
40 The aim of the present study was to retrospectively evaluate the safety, tolerability, and
41 effectiveness of bedaquiline-containing regimens in a large observational cohort of MDR- and
42 XDR-TB patients treated under programmatic conditions.

43
44
45 The results of our study demonstrate that, overall, bedaquiline-containing regimens achieve a
46 relatively higher proportion of treatment success with a relatively lower proportion of adverse
47 events within different settings than previously described.

1
2
3 Of note, culture conversion rates were higher than those reported in cohorts with an analogous
4 degree of disease severity; with time to sputum smear and culture conversion identical or earlier to
5 those observed in comparable cohorts; the proportion of treatment success was higher, and the
6 percentage of adverse outcomes (death, failure) lower than those seen in available study cohorts
7 with the matching disease severity; adverse events due to bedaquiline requiring interruption of the
8 drug were relatively uncommon (5.8%) [14,15].

9
10 This is, to our knowledge, the largest study describing effectiveness, safety, and tolerability of
11 bedaquiline within optimised background regimens (almost double the size of the largest one
12 published so far) and the first one in the scientific literature reporting on the programmatic use of
13 bedaquiline for the treatment of M/XDR-TB patients on 5 continents.

14
15 Regarding effectiveness, although difficult to attribute to bedaquiline given the causality of the
16 results observed, we can report that bedaquiline-containing regimens achieved culture conversion
17 rates exceeding 90% at the end of treatment and treatment success >70%, higher than those
18 observed in other MDR-TB cohorts [3,4,19,21].

19
20 In comparison with Menzies' data on Individual Patient Data analysis (where there was a 43%
21 success in XDR), in our bedaquiline treated XDR-TB cohort the success rate was 71.3% [3,4].

22
23 In a phase 2 double blind, randomised control trial study by Diacon et al. [20] the median time to
24 culture conversion in 79 bedaquiline-treated MDR-TB patients was 83 days; this compares with our
25 median time of 60 days. In the study by Diacon et al. the culture conversion at the end of 24 weeks
26 was 79% and at 120 weeks was 58% VS. 91.7% at the end of therapy in our study, and the cure
27 rates 58% and 62,4%, respectively [20].

28
29 Pym et al. conducted a phase 2 trial to assess safety and efficacy of bedaquiline in 233 patients,
30 culture conversion was seen in 72.2% at 120 weeks, 8.6% of patients discontinued treatment and
31 6.9% of patients died [19].

32
33 Regarding safety, in the Diacon's study [20] 13% of patients in the bedaquiline group died (10 of 79
34 VS. 2 of 81 in the placebo group) versus 33 (13.4%) out of the 247 who had an evaluable outcome
35 in our cohort.

36
37 The most frequent adverse events in our study were nausea (31.5%), otovestibular toxicity (23.3%),
38 peripheral neuropathy (23.3%), vomiting (21.2%) and arthralgia (20.4%), their frequencies being
39 slightly lower than those described during Diacon et al's licensing study with 41% nausea, 29%
40 vomiting and 37% arthralgia [21]. Importantly, in the Diacon's study the proportion of the adverse
41 events was similar in the group VS. placebo patients, suggesting they were probably due to the
42 background regimen.

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 In this context, other second-line drugs like fluoroquinolones or clofazimine might contribute to
4 cardiologic or other adverse events [14,15,39] and invite caution and ECG monitoring.

5
6 Our study confirms that bedaquiline-containing regimens are effective, as demonstrated by the fact
7 that a sizeable number of patients were treated with salvage regimens due to previous treatment
8 failure, unfavourable resistance profile, toxicity, or all three.

9
10 The larger group of patients in real programmatic conditions around the globe reinforces previous
11 findings that bedaquiline is well tolerated and adverse events are less common than previously
12 thought.

13
14 Enthusiasm over bedaquiline and delamanid has been curtailed following concerns of potential
15 cardiotoxicity. Both new drugs are associated with QT prolongation, which may lead to arrhythmia
16 and sudden death, a major reason why their association has not been recommended. Moreover, the
17 new drugs are likely to be associated with a fluoroquinolone and clofazimine, both known to
18 prolong QT intervals. Our results appear to show that the risk is probably lower than previously
19 known, although the specific role of the many drugs with QT prolonging potential (and their
20 summation or synergistic effect) still needs to be fully understood.

21
22 QT prolongation occurred in 9.7% of patients. However, interruption of bedaquiline due to AEs,
23 occurred in 25 (5.8%) patients.

24
25 According to the information available, a single case out of 33 who died had ECG abnormalities,
26 although the QT was below the 500 msec threshold and a single QTcF measurement was above 450
27 but below 500 msec. The revision of clinical and ECG history of the patient makes relationship
28 between bedaquiline use and fatal arrhythmia unlikely.

29
30 Although information on QT is available in 64% of cases, and the timing of their assessment not
31 standardised, it seems the majority of cases died for non heart-related reasons.

32
33 Close monitoring of drug safety should be implemented widely, particularly for rare adverse events.
34 A comprehensive, population-level pharmacological surveillance in the post-marketing phase might
35 allow a better assessment of the safety and tolerability profile of bedaquiline, alone or in
36 combination with other potentially cardio-toxic anti-TB drugs.

37
38 We underline the importance of using, in future studies, a standardised ECG monitoring protocol
39 allowing to exclude inter- and intra-day variability in QTc measurements. For study purposes 24
40 hour Holter monitoring is probably the best strategy to assess the true impact of drugs on QTc. This
41 is clearly not feasible under programmatic conditions.

42
43 The strengths of the study are the large sized cohort, the inclusion of cases from several countries
44 (ranging from 10% of all patients receiving bedaquiline in South Africa to 100% of bedaquiline-
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 treated patients in Argentina, Greece, Portugal and Spain), and the detailed information collected
4 from the participating centres. The large sample size allows, for the first time, to compare treatment
5 outcomes from different settings.
6

7
8 Some variables, like the drug-resistance patterns, the number of previous anti-treatment cycles and
9 the HIV sero-prevalence varied among the settings participating in the study.
10

11 However, the observational and retrospective design of the study has inbuilt limitations (recent
12 guideline changes, different resource settings, different standards of care, dataset differences) so
13 that the study findings need to be confirmed by larger randomised controlled clinical trials. The
14 different operating procedures adopted in different settings, as well as the heterogeneous drug
15 resistance patterns, could underestimate the real benefits of the bedaquiline-containing regimens.
16 However, the new information provided by this observational study allows clinicians managing
17 difficult-to-treat TB cases in programmatic conditions to better understand how to use bedaquiline
18 in case the minimum number of active drugs necessary to design an effective regimen is lacking
19 [1,8,15].
20
21
22
23
24
25

26 Although new compounds will hopefully appear soon to support the move towards TB Elimination
27 [50], bedaquiline confirms to have potential given its ‘core drug’ characteristics [12] to manage
28 MDR- and XDR-TB cases even in field conditions, and eventually to be used in newly designed
29 anti-TB regimens of the future.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. World Health Organization. Global tuberculosis report 2016. WHO/HTM/TB/2016.13 Geneva, World Health Organization 2016.
2. Falzon D, Linh Nhat N, Jaramillo E, Weyer K. The global response to rifampicin-resistant tuberculosis: Current situation and recent trends. *Eur Respir J* 2016, 48 (suppl 60) PA1903; DOI: 10.1183/13993003.congress-2016.PA1903
3. Migliori GB, Sotgiu G, Gandhi NR, Falzon D, DeRiemer K, Centis R, Hollm-Delgado MG, Palmero D, Pérez-Guzmán C, Vargas MH, D'Ambrosio L, Spanevello A, Bauer M, Chan ED, Schaaf HS, Keshavjee S, Holtz TH, Menzies D; The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Drug resistance beyond extensively drug resistant tuberculosis: individual patient data meta-analysis. *Eur Respir J* 2013;42:169–79.
4. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, Hollm-Delgado MG, Keshavjee S, DeRiemer K, Centis R, D'Ambrosio L, Lange CG, Bauer M, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. *Eur Respir J*. 2013;42(1):156-68.
5. Diel R, Rutz S, Castell S, Tom Schaberg T. Tuberculosis: cost of illness in Germany. *Eur Respir J* 2012; 40 (1) 143-15.
6. Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. *Eur Respir J* 2014; 43 (2) 554-565.
7. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. *Eur Respir J*. 2011;38:516–528.
8. Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, Weyer K. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. *Eur Respir J* 2017 in press
9. Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in Italy resistant to all tested drugs. *Euro Surveill* 2007;12(5):E070517.1.
10. Pooran A, Pieterse E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? *PLoS One*. 2013;8(1):e54587. doi: 10.1371/journal.pone.0054587
11. Shean K, Streicher E, Pieterse E, Symons G, van Zyl Smit R, Theron G, Lehloeny R, Padanilam X, Wilcox P, Victor T.C, van Helden P, Groubusch M, Warren R, Badri M, Dheda K. Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa. *PLoS One* 2013 7;8(5):e 63057

- 1
2
3 12. Caminero J, Scardigli A. Classification of antituberculosis drugs: a new proposal based on
4 the most recent evidence. *Eur Respir J* 2015; 46: 887–893.
- 5
6 13. Sotgiu G, Pontali E, Migliori G.B. Linezolid to treat MDR-/XDR-Tuberculosis: available
7 evidence and future scenarios. *Eur Respir J* 2015; 45: 25–29.
- 8
9 14. Pontali E, Sotgiu G, D'Ambrosio L, Centis R, Migliori G.B. Bedaquiline and MDR-TB: a
10 systematic and critical analysis of the evidence. *Eur Respir J* 2016; 47: 394–402. doi:
11 10.1183/13993003.01891-2015.
- 12
13 15. Pontali E, D'Ambrosio L, Centis R, Sotgiu G, Migliori G.B. Multidrug-resistance
14 tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. *Eur*
15 *Respir J* 2017 in press.
- 16
17 16. Esposito S, D'Ambrosio L, Tadolini M, Schaaf HS, Caminero Luna J, Marais B, Centis R,
18 Dara M, Matteelli A, Blasi F, Migliori GB. ERS/WHO Tuberculosis Consilium assistance
19 with extensively drug-resistant tuberculosis management in a child: case study of
20 compassionate delamanid use. *Eur Respir J*. 2014;44(3):811-5.
- 21
22 17. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A,
23 Leimane V, Kurve A, Levina K, Geiter L.J, Manissero D, Wells C.D. Delamanid improves
24 outcomes and reduces mortality in multidrug-resistant tuberculosis. *Eur Respir J* 2013; 41:
25 1393–1400.
- 26
27 18. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant
28 pulmonary tuberculosis. *N Engl J Med* 2012;366:2151–60.
- 29
30 19. Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I,
31 Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van
32 Baelen B, van Heeswijk RP, Dannemann B; TMC207-C209 Study Group. Bedaquiline in the
33 treatment of multidrug- and extensively drug-resistant tuberculosis. *Eur Respir J*.
34 2016;47(2):564-74. doi: 10.1183/13993003.00724-2015.
- 35
36 20. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L et al. The
37 diarylquinoline TMC207 for multidrug-resistant tuberculosis. *N Engl J Med*.
38 2009;360(23):2397–2405.
- 39
40 21. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I et al. Multidrug-
41 resistant tuberculosis and culture conversion with bedaquiline. *N Engl J Med*.
42 2014;371(8):723–732.
- 43
44 22. Guglielmetti L, Le Dù D, Jachym M, Henry B, Martin D, Caumes E et al. MDR-TB
45 Management Group of the French National Reference Center for Mycobacteria and the
46 Physicians of the French MDR-TB Cohort. Compassionate use of bedaquiline for the
47 treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis
48 of a French cohort. *Clin Infect Dis*. 2015;60 (2):188–194.
- 49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 23. Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with
4 bedaquiline in a high HIV prevalence setting: an interim cohort analysis. *Int J Tuberc Lung*
5 *Dis.* 2015;19(8):979–985.
6
- 7
8 24. Tiberi S, De Lorenzo S, Centis R, Viggiani P, D'Ambrosio L, Migliori GB. Bedaquiline in
9 MDR/XDR-TB cases: first experience on compassionate use. *Eur Respir J.* 2014;43(1):289-
10 92.
11
- 12
13 25. Tiberi S, D'Ambrosio L, De Lorenzo S, Viggiani P, Centis R, Migliori GB. Tuberculosis
14 elimination, patients' lives and rational use of new drugs: revisited. *Eur Respir J.* 2016; 47:
15 664–667.
16
- 17
18 26. Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J,
19 Girardi E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C for the
20 TBNET Study Group. A retrospective TBNET assessment of linezolid safety, tolerability
21 and efficacy in MDR-TB. *Eur Resp J* 2009;34(2):387-393.
22
- 23
24 27. Villar M, Sotgiu G, D'Ambrosio L, Raymundo E, Fernandes L, Barbedo J, Diogo N, Lange
25 C, Centis R, Migliori GB. Linezolid safety, tolerability and efficacy to treat multidrug- and
26 extensively drug-resistant tuberculosis. *Eur Respir J.* 2011 ;38(3):730-3.
27
- 28
29 28. De Lorenzo S, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB. On linezolid efficacy and
30 tolerability. *Eur Respir J.* 2012;39(3):770-772.
31
- 32
33 29. Sotgiu G, Centis R, D'Ambrosio L, Alffenaar J, Anger H, Caminero J, Castiglia P, De
34 Lorenzo S, Ferrara G, Koh W, Schechter G, Shim T, Singla R, Skrahina A, Spanevello A,
35 Udhwadia Z, Villar M, Zampogna E, Zellweger J, Zumla A, Migliori GB. Efficacy, safety and
36 tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic
37 review and meta-analysis. *Eur Respir J.* 2012;40(6):1430-42.
38
- 39
40 30. Sotgiu G, Centis R, D'Ambrosio L, Spanevello A, Migliori GB; International Group for the
41 study of Linezolid. Linezolid to treat extensively drug-resistant TB: retrospective data are
42 confirmed by experimental evidence. *Eur Respir J.* 2013;42(1):288-90.
43
- 44
45 31. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-
46 resistant tuberculosis. *N Engl J Med* 2012; 367: 1508–1518.
47
- 48
49 32. Sotgiu G, Centis R, D'Ambrosio L, Castiglia P, Migliori GB. Low minimal inhibitory
50 concentrations of linezolid against multidrug-resistant tuberculosis strains. *Eur Respir J.*
51 2015;45(1):287-9.
52
- 53
54 33. De Lorenzo S, Alffenaar JW, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Bolhuis MS, van
55 Altena R, Viggiani P, Piana A, Spanevello A, Migliori GB. Efficacy and safety of
56 meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-
57 /XDR-TB. *Eur Respir J.* 2013; 41(6):1386-92.
58
- 59
60 34. Tiberi S, D'Ambrosio L, De Lorenzo S, Viggiani P, Centis R, Sotgiu G, et al. Ertapenem in
the treatment of multidrug-resistant tuberculosis: first clinical experience. *Eur Respir J.* 2016
;47(1):333-6. doi: 10.1183/13993003.01278-2015.

- 1
2
3 35. S. P van Rijn, R. van Altena, O.W. Akkerman, D. van Soolingen, T. van der Laan, W.C.M de
4 Lange, J.G.W.Kosterink, T.S. van der Werf, J.W.C Alffenaar. Pharmacokinetics evaluation of
5 ertapenem in patients with treatment of multidrug-resistant tuberculosis. *Eur Respir J*
6 2016;47(4):1229-34. doi: 10.1183/13993003.01654-2015.
7
8
9 36. Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Alarcon Guizado V, Alffenaar JW, et al.
10 Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of
11 MDR- and XDR-TB. *Eur Respir J*. 2016;47(4):1235-43. doi: 10.1183/13993003.02146-
12 2015.
13
14 37. Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Arbex MA, Alarcon Arrascue E, et al.
15 Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background
16 Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant
17 and Extensively Drug-Resistant Tuberculosis. *Clin Infect Dis*. 2016;1;62(9):1188-90. doi:
18 10.1093/cid/ciw088.
19
20
21 38. Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, Alffenaar
22 JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon
23 Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A,
24 Artsukevich J, Auchynka V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G,
25 Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A,
26 Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB. Comparison
27 of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-
28 containing regimens in the treatment of MDR- and XDR-TB. *Eur Respir J*.
29 2016;47(6):1758-66. doi: 10.1183/13993003.00214-2016
30
31
32
33 39. Dalcolmo M, Gayoso R, Sotgiu G, D'Ambrosio L, Rocha JL, Borga L, Fandinho F, Ueleres
34 Braga J, Neder Galesi VM, Barreira D, Arakaki Sanchez D, Dockhorn F, Centis C,
35 Caminero JA, Migliori GB. Effectiveness and safety of clofazimine within a standard
36 multidrug-resistant tuberculosis regimen in Brazil: first nation-wide report on over 2,500
37 cases. *Eur Respir J* 2017 in press.
38
39
40
41 40. Winters N, Butler-Laporte G, Menzies D. Efficacy and safety of World Health Organization
42 group 5 drugs for multidrug-resistant tuberculosis treatment. *Eur Respir J*. 2015;
43 46(5):1461-1470.
44
45
46 41. Alsaad N, Wilffert B, van Altena R, de Lange W.C.M, van der Werf T.S, Kosterink J.G.W,
47 Alffenaar J.W.C. Potential antimicrobial agents for the treatment of multidrug-resistant
48 Tuberculosis. *Eur Respir J* 2014; 43: 884–897.
49
50
51 42. Alsaad N, van Altena R, Pranger A.D, van Soolingen D, de Lange W.C.M, van der Werf
52 T.S, Kosterink J.G.W and Alffenaar J.W.C. Evaluation of co-trimoxazole in the treatment of
53 multidrug-resistant tuberculosis. *Eur Respir J* 2013; 42: 504–512.
54
55
56 43. Krieger D, Vesenbeckh S, Schönfeld N, Bettermann G, Bauer T.T, Rüssmann H, Mauch H.
57 Mefloquine as a potential drug against multidrug-resistant tuberculosis. *Eur Respir J* 2015;
58 46: 1503–1505.
59
60

- 1
2
3 44. Tadolini M, Lingsang RD, Tiberi S, Enwerem M, D'Ambrosio L, Sadutshang TD, et al.
4 First case of extensively drug-resistant tuberculosis treated with both delamanid and
5 bedaquiline. *Eur Respir J.* 2016;48(3):935-8. doi: 10.1183/13993003.00637-2016.
6
7
8 45. Wallis RS. Cardiac safety of extensively drug-resistant tuberculosis regimens including
9 bedaquiline, delamanid and clofazimine. *Eur Respir J.* 2016;48(5):1526-1527. doi:
10 10.1183/13993003.01207-2016.
11
12 46. Tadolini M, Lingsang RD, Tiberi S, Enwerem M, D'Ambrosio L, Sadutshang TD, Centis R,
13 Migliori GB. Cardiac safety of extensively drug-resistant tuberculosis regimens including
14 bedaquiline, delamanid and clofazimine. *Eur Respir J.* 2016 Nov;48(5):1527-1529. doi:
15 10.1183/13993003.01552-2016.
16
17
18 47. Rendon A, Fuentes Z, Torres-Duque C.A, del Granado M, Victoria J, Duarte R, Migliori
19 G.B. Roadmap for tuberculosis elimination in Latin American and Caribbean Countries: a
20 strategic alliance *Eur Respir J.* 2016; 48: 1282–1287 | DOI: 10.1183/13993003.01549-2016.
21
22
23 48. Dalcolmo M, Gayoso R, Sotgiu G, D'Ambrosio L, Rocha JL, Borga L, Fandinho F, Ueleres
24 Braga J, Arakaki Sanchez D, Dockhorn F, Centis R, Migliori GB. Resistance profile to the
25 drugs composing the 'shorter' regimen for multidrug-resistant TB in Brazil, 2000-2015. *Eur*
26 *Respir J* 2017 in press.
27
28
29 49. Ndjeka N, the Bedaquiline Clinical Access Programme, the Bedaquiline Implementers of the
30 South African National TB Programme. Incorporation of Bedaquiline in the South African
31 National TB Programme. 23rd Conference on Retroviruses and Opportunistic Infections
32 (CROI 2016), 22-25 February 2016, Boston. Abstract #754.
33
34
35 50. Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon
36 D, Gaudreau M.A, Goletti D, González Ochoa E, LoBue P, Matteelli A, Njoo H, Solovic I,
37 Story A, Talal Tayeb T, van den Werf M.J, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati
38 MRM, Aliberti S, Arrazola de Onate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J,
39 Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle U, De Paoli L,
40 Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Gogvadze L, del Granado
41 M, Haas W, Järvinen A, Kwon G-Y, Mosca D, Nahid P, Nishikiori N, Nogueira I, O'Donnell
42 J, Pace-Asciak A, Pompa MG, Popescu G, Robalo Cordeiro C, Rønning K, Ruhwald M,
43 Sculier JP, Simunović A, Smith-Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K,
44 Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M and
45 Raviglione MC.. Towards tuberculosis elimination: an action framework for low-incidence
46 countries. *Eur Respir J.* 2015;45(4):928-52.
47
48
49
50
51
52
53
54

55 Acknowledgments

56
57 The authors alone are responsible for the views expressed in this publication and they do not
58 necessarily represent the decisions and policies of their institutions.
59
60

Table 1. Demographic, epidemiological, and clinical characteristics of 428 culture-confirmed multidrug-resistant tuberculosis patients exposed to bedaquiline-containing regimens.

Variables		
<i>Median (IQR) age</i>		35 (27-44)
<i>Male, n (%)</i>		263 (61.5)
<i>Median (IQR) body weight at admission, kg</i>		56 (47-65)
<i>Median (IQR) height, cm</i>		169 (160-176)
<i>Migrant, n (%)</i>		45 (10.5)
<i>Employed, n (%)</i>		110 (26.6)
<i>Prisoner, n (%)</i>		23 (5.6)
<i>Pregnant, n (%)</i>		1 (0.75)
<i>Thyroid disease, n (%)</i>		12 (2.9)
<i>Heart disease, n (%)</i>		40 (12.6)
<i>Pre-existing ECG abnormality, n (%)</i>		13 (4.1)
<i>Alcoholism, n (%)</i>		132 (36.4)
<i>Drug abuse, n (%)</i>		75 (18.2)
<i>Methadone use, n (%)</i>		0 (0.0)
<i>Diabetes, n (%)</i>		26 (6.3)
<i>HIV infection testing, n (%)</i>		425 (99.3)
<i>HIV-positive, n (%)</i>		94 (22.1)
<i>Median (IQR) CD4 count at baseline, mmc</i>		269 (168-470)
<i>Median (IQR) nadir CD4+ cell counts, mmc</i>		222 (160-402)
<i>Anti-retroviral therapy exposure, n (%)</i>		92 (97.9)
<i>Prior anti-TB therapy, n (%)</i>		334 (78.0)
<i>Median (IQR) n times treated >1 month</i>		2 (1-2)
<i>Prior TB treatment outcome, n (%)</i>	<i>Success</i>	68 (25.9)
	<i>Cured</i>	41 (15.6)
	<i>Completed</i>	27 (10.3)
	<i>Defaulted</i>	35 (13.3)
	<i>Transferred out</i>	20 (7.6)
	<i>Failed</i>	140 (53.2)
<i>Pulmonary surgery, n (%)</i>		55 (13.0)
<i>Previous MDR-TB, n (%)</i>		169 (53.3)
<i>Pulmonary involvement, n (%)</i>		426(99.5)
<i>Extra-pulmonary involvement, n (%)</i>		11 (2.6)
<i>Radiology involvement, n (%)</i>	<i>Cavitary lesion</i>	81 (24.5)
	<i>Bilateral pulmonary involvement with cavitary lesions</i>	147 (44.4)
	<i>Bilateral pulmonary involvement</i>	56 (16.9)
	<i>Noncavitary nonbilateral pulmonary</i>	47 (14.2)

<i>Sputum-smear positive, n (%)</i>	305 (72.1)
<i>Sputum culture positive, n (%)</i>	421 (98.4)
<i>Resistance to streptomycin, n (%)</i>	185 (94.4)
<i>Resistance to ethambutol, n (%)</i>	186 (77.5)
<i>Resistance to pyrazinamide, n (%)</i>	145 (70.4)
<i>Resistance to fluoroquinolones, n (%)</i>	267 (64.5)
<i>Resistance to amikacin, n (%)</i>	131 (44.4)
<i>Resistance to capreomycin, n (%)</i>	127 (41.6)
<i>Resistance to kanamycin, n (%)</i>	179 (59.3)
<i>Resistance to ethionamide, n (%)</i>	135 (59.7)
<i>Resistance to cycloserine, n (%)</i>	20 (12.3)
<i>Resistance to para-aminosalicylic acid, n (%)</i>	70 (35.7)
<i>Resistance to linezolid, n (%)</i>	4 (10.5)
<i>Resistance to rifabutin, n (%)</i>	32 (91.4)
<i>XDR-TB, n (%)</i>	195 (45.6)
<i>MDR/XDR-TB contacts, n (%)</i>	105 (25.6)
<i>Median (IQR) hospital stay</i>	179 (92-280)

IQR: interquartile range; XDR-TB: extensively drug-resistant tuberculosis; MDR: multidrug-resistant

Table 2. Treatment outcome and conversion rates of 428 culture-confirmed multidrug-resistant tuberculosis patients exposed to bedaquiline-containing regimens.

Variables		
<i>Sputum smear conversion 30 days, n (%)</i>		206 (63.6)
<i>Sputum culture conversion 30 days, n (%)</i>		117 (30.1)
<i>Sputum smear conversion 60 days, n (%)</i>		257 (81.1)
<i>Sputum culture conversion 60 days, n (%)</i>		213 (56.7)
<i>Sputum smear conversion 90 days, n (%)</i>		265 (85.5)
<i>Sputum culture conversion 90 days, n (%)</i>		298 (80.5)
<i>Sputum smear conversion at the end of treatment, n (%)</i>		126 (90.0)
<i>Sputum culture conversion at the end of treatment, n (%)</i>		191 (91.8)
<i>Median (IQR) time to sputum smear conversion, days</i>		34 (30-60)
<i>Median (IQR) time to sputum culture conversion, days</i>		60 (33-90)
<i>Treatment outcome, n (%)</i>	<i>Success</i>	176 (71.3)
	<i>Cured</i>	154 (62.4)
	<i>Completed</i>	22 (8.9)
	<i>Died</i>	33 (13.4)
	<i>Defaulted</i>	18 (7.3)
	<i>Failure</i>	19 (7.7)
	<i>Transferred out</i>	1 (0.4)
<i>Median (IQR) months of treatment after MDR-TB diagnosis</i>		18 (10-22)
<i>Mean (SD) body weight at the end of treatment, kg</i>		61.9 (13.9)

IQR: interquartile range; MDR-TB: multidrug-resistant tuberculosis; SD: standard deviation

Table 3. Treatment outcomes of 428 culture-confirmed MDR- and XDR-TB patients exposed to bedaquiline-containing regimens in different settings.

Treatment outcome	Africa (n=113)	Eastern Europe (n=85)	Other settings (n=49)	p-value
Total cohort				
<i>Treatment success</i>	73 (64.6)	65 (76.5)	38 (77.6)	0.10
<i>Cured</i>	73 (64.6)	54 (63.5)	27 (55.1)	<0.0001
<i>Completed</i>	-	11 (12.9)	11 (22.5)	
<i>Died</i>	27 (23.9)	3 (3.5)	3 (6.1)	
<i>Defaulted</i>	9 (8.0)	8 (9.4)	1 (2.0)	
<i>Failure</i>	3 (2.7)	9 (10.6)	7 (14.3)	
<i>Transferred out</i>	1 (0.9)	-	-	
MDR-TB				
<i>Treatment success</i>	36 (58.1)	28 (71.8)	22 (81.5)	0.07
<i>Cured</i>	36 (58.1)	20 (51.3)	11 (40.7)	<0.0001
<i>Completed</i>	-	8 (20.5)	11 (40.7)	
<i>Died</i>	17 (27.4)	3 (7.7)	1 (3.7)	
<i>Defaulted</i>	7 (11.3)	3 (7.7)	1 (3.7)	
<i>Failure</i>	1 (1.6)	5 (12.8)	3 (11.1)	
<i>Transferred out</i>	1 (1.6)	-	-	
XDR-TB				
<i>Treatment success</i>	37 (72.6)	37 (80.4)	16 (72.7)	0.63
<i>Cured</i>	37 (72.6)	34 (73.9)	16 (72.7)	0.006
<i>Completed</i>	-	3 (6.5)	-	
<i>Died</i>	10 (19.6)	-	2 (9.1)	
<i>Defaulted</i>	2 (3.9)	5 (10.9)	-	
<i>Failure</i>	2 (3.9)	4 (8.7)	4 (18.2)	
<i>Transferred out</i>	-	-	-	
MDR-TB: multidrug-resistant tuberculosis; XDR-TB: extensively drug-resistant tuberculosis				

Table 4. Safety and tolerability profile of bedaquiline-containing regimens in a cohort of 428 culture-confirmed MDR-TB patients.

<i>Interruption of bedaquiline, n (%)</i>	51 (11.9)
<i>Interruption of bedaquiline due to adverse events, n (%)</i>	25 (5.8)
<i>Adverse events presumably due to bedaquiline, n (%)</i>	80 (19.4)
<i>Bedaquiline restarted if interrupted, n (%)</i>	25 (49)
<i>Median (IQR) total bedaquiline exposure, days</i>	168 (86-180)
Renal and electrolyte abnormalities	
<i>Creatinine >1.4x ULN, n (%)</i>	91 (22.1)
<i>Lipase >1.6x ULN, n (%)</i>	1 (0.4)
<i>ALT >3x ULN, n (%)</i>	92 (22.3)
<i>Bilirubin >2x ULN, n (%)</i>	47 (11.4)
<i>Median (IQR) albumin, gr/dl</i>	36 (30-40)
<i>Potassium <3.4 or >5.6 mmol/L, n (%)</i>	98 (23.8)
<i>Magnesium <0.59 mmol/L, n (%)</i>	21 (10.6)
<i>Calcium <1.75 mmol/L, n (%)</i>	23 (7.6)
Other adverse events	
<i>Nausea, n (%)</i>	130 (31.5)
<i>Neuropathy peripheral, n (%)</i>	96 (23.3)
<i>Oto-vestibular toxicity, n (%)</i>	96 (23.3)
<i>Vomiting, n (%)</i>	87 (21.2)
<i>Anaemia, n (%)</i>	86 (20.9)
<i>Arthralgia, n (%)</i>	84 (20.4)
<i>Skin rash, n (%)</i>	63 (15.3)
<i>Pancreatitis, n (%)</i>	4 (1.3)
<i>Diarrhoea, n (%)</i>	56 (13.6)
<i>Renal failure, n (%)</i>	47 (11.4)
<i>Thrombocytopenia, n (%)</i>	41 (9.9)
<i>Neutropenia, n (%)</i>	40 (9.7)
<i>Lymphocytopenia, n (%)</i>	40 (9.7)
<i>QT prolongation, n (%)</i>	24 (9.7)
<i>Hypothyroidism, n (%)</i>	38 (9.3)
<i>Psychiatric disorder, n (%)</i>	29 (7.0)
<i>Tendinopathy, n (%)</i>	18 (4.4)
<i>Optic neuropathy, n (%)</i>	10 (2.4)
<i>Deep vein thrombosis, n (%)</i>	7 (1.7)
<i>Hallucinations, n (%)</i>	2 (0.5)
<i>Stroke, n (%)</i>	1 (0.3)

1
2
3 **Figure 1. Sputum smear and culture conversion rates of 428 culture-confirmed multidrug-**
4 **resistant tuberculosis patients exposed to bedaquiline-containing regimens.**
5
6
7

8
9 **Figure 2. Median values of the QTcF interval and its temporal trends in the cohort in the**
10 **initial 12 weeks of treatment**
11

12
13
14 **Median values**

	Baseline	Week 4	Week 8	Week 12
<i>Median (IQR) QTcF, msec</i>	401.5 (372.0-437.0)	424.0 (395.0-456.0)	430.0 (401.0-450.0)	425.5 (389.0-449.0)

15
16
17
18
19
20
21
22
23 **Temporal trends**
24
25
26
27
28

29 The coloured dots indicate outlier patients

30 IQR: interquartile range; QTcF: QT interval in the electrocardiogram corrected according to Fredericia
31 formula
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Sputum smear and culture conversion rates of 428 culture-confirmed multidrug-resistant tuberculosis patients exposed to bedaquiline-containing regimens.

Figure 1
205x119mm (150 x 150 DPI)




Figure 2. Median values of the QTcF interval and its temporal trends in the cohort in the initial 12 weeks of treatment

Figure 2
235x148mm (125 x 125 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60